Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), which is in the healthcare services business, and is based in United States, saw significant share price movement during recent months on the NASDAQGM, rising to highs of US$66.12 and falling to the lows of US$48.92. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Tabula Rasa HealthCare's current trading price of US$51.86 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Tabula Rasa HealthCare’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.
Is Tabula Rasa HealthCare still cheap?
Great news for investors – Tabula Rasa HealthCare is still trading at a fairly cheap price. According to my valuation, the intrinsic value for the stock is $73.41, which is above what the market is valuing the company at the moment. This indicates a potential opportunity to buy low. However, given that Tabula Rasa HealthCare’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.
Can we expect growth from Tabula Rasa HealthCare?
Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. However, with a negative profit growth of -2.6% expected over the next couple of years, near-term growth certainly doesn’t appear to be a driver for a buy decision for Tabula Rasa HealthCare. This certainty tips the risk-return scale towards higher risk.
What this means for you:
Are you a shareholder? Although TRHC is currently undervalued, the negative outlook does bring on some uncertainty, which equates to higher risk. I recommend you think about whether you want to increase your portfolio exposure to TRHC, or whether diversifying into another stock may be a better move for your total risk and return.
Are you a potential investor? If you’ve been keeping an eye on TRHC for a while, but hesitant on making the leap, I recommend you research further into the stock. Given its current undervaluation, now is a great time to make a decision. But keep in mind the risks that come with negative growth prospects in the future.
Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Tabula Rasa HealthCare. You can find everything you need to know about Tabula Rasa HealthCare in the latest infographic research report. If you are no longer interested in Tabula Rasa HealthCare, you can use our free platform to see my list of over 50 other stocks with a high growth potential.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at firstname.lastname@example.org. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.